Comparing the effects of infliximab and alpha interferon in the treatment of Behçet’s Disease

Not Applicable

• Conditions: Behçet disease; Musculoskeletal Diseases

• Registration Number: ISRCTN49793874
• Lead Sponsor: niversity of Liverpool

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2016-03-09
• Last Update Posted: 24 November 2020
• Study Completion: 2021-06-30

Recruitment & Eligibility

• Status: Ongoing
• Sex: All
• Target Recruitment: 79

Inclusion Criteria

1. Diagnosed to have BD by International Study Group (ISG) criteria or International Criteria for BD (ICBD)
2. Have refractory disease as defined by the UK Centres of Excellence criteria (failure to respond to steroid and/or immunosuppressive therapy with significant or major organ­threatening disease) and therefore qualify for biologic therapy with either IFX or aIFN
3. Able to give informed consent
4. Have not previously received a biologic agent
5. Aged over 18 years

Exclusion Criteria

1. Have a contraindication to either IFX or aIFN (eg active infection, severe liver disease, neutropenia, previous malignancy)
2. Are likely to not comply: for example cannot attend assessments because of excessive travel requirements
3. Are already, or likely to become, pregnant during the study
4. Express a strong preference for one of the two potential therapies
5. Have heart disease or severe heart failure
6. Have been diagnosed with Multiple sclerosis
7. Have evidence of infection with HIV

Study & Design

• Study Type: Interventional
• Study Design: Not specified